Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125207201 | 12520720 | 1 | I | 20160606 | 20160628 | 20160701 | 20160701 | EXP | FR-009507513-1606FRA013654 | MERCK | 27.81 | YR | M | Y | 0.00000 | 20160701 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125207201 | 12520720 | 1 | PS | EMEND | APREPITANT | 1 | Oral | 80 MG, QD | U | U | 21549 | 80 | MG | CAPSULE | QD | ||||
| 125207201 | 12520720 | 2 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MG PER CYCLE (1ST CYCLE) | U | U | 5J271M5 | 0 | |||||||
| 125207201 | 12520720 | 3 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MG PER CYCLE (2ND CYCLE) | U | U | 5J271M5 | 0 | |||||||
| 125207201 | 12520720 | 4 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MG PER CYCLE (3RD CYCLE) | U | U | 5J271M5 | 0 | |||||||
| 125207201 | 12520720 | 5 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MG PER CYCLE (4TH CYCLE) | U | U | 5J271M5 | 0 | |||||||
| 125207201 | 12520720 | 6 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MG PER CYCLE (5TH CYCLE) | U | U | 5J271M5 | 0 | |||||||
| 125207201 | 12520720 | 7 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Intravenous (not otherwise specified) | 10000 MG PER CYCLE (6TH CYCLE) | U | U | 5J271M5 | 0 | |||||||
| 125207201 | 12520720 | 8 | SS | DOXORUBICIN TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MG PER CYCLE (1ST CYCLE) | U | U | 0 | 150 | MG | ||||||
| 125207201 | 12520720 | 9 | SS | DOXORUBICIN TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MG PER CYCLE (2ND CYCLE) | U | U | 0 | 150 | MG | ||||||
| 125207201 | 12520720 | 10 | SS | DOXORUBICIN TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MG PER CYCLE (3RD CYCLE) | U | U | 0 | 150 | MG | ||||||
| 125207201 | 12520720 | 11 | SS | DOXORUBICIN TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MG PER CYCLE (4TH CYCLE) | U | U | 0 | 150 | MG | ||||||
| 125207201 | 12520720 | 12 | SS | DOXORUBICIN TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MG PER CYCLE (5TH CYCLE) | U | U | 0 | 150 | MG | ||||||
| 125207201 | 12520720 | 13 | SS | DOXORUBICIN TEVA | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | 150 MG PER CYCLE (6TH CYCLE) | U | U | 0 | 150 | MG | ||||||
| 125207201 | 12520720 | 14 | SS | ZOPHREN (ondansetron) | ONDANSETRON | 1 | Intravenous (not otherwise specified) | 8 MG, QD (STREGTH 2MG/ML) | U | 0 | 8 | MG | SOLUTION FOR INJECTION | QD | |||||
| 125207201 | 12520720 | 15 | SS | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Intravenous (not otherwise specified) | 80 MG, QD | U | U | 0 | 80 | MG | POWDER FOR INJECTION | QD | ||||
| 125207201 | 12520720 | 16 | SS | MESNA. | MESNA | 1 | Intravenous (not otherwise specified) | 5000 MG/M2 PER CYCLE | U | U | 0 | ||||||||
| 125207201 | 12520720 | 17 | C | ISENTRESS | RALTEGRAVIR POTASSIUM | 1 | Oral | 2 DF, QD (400 MG, BID (MORNING AND EVENING)) | U | 0 | 2 | DF | TABLET | QD | |||||
| 125207201 | 12520720 | 18 | C | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 200 MG, QD | U | 0 | 200 | MG | QD | ||||||
| 125207201 | 12520720 | 19 | C | LYRICA | PREGABALIN | 1 | Oral | 200 MG, BID | U | 0 | 200 | MG | BID | ||||||
| 125207201 | 12520720 | 20 | C | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 1 TABLET, 3 TIMES WEEKLY | U | 0 | 1 | DF | TABLET | TIW |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125207201 | 12520720 | 1 | Prophylaxis of nausea and vomiting |
| 125207201 | 12520720 | 2 | Sarcoma |
| 125207201 | 12520720 | 8 | Sarcoma |
| 125207201 | 12520720 | 14 | Prophylaxis of nausea and vomiting |
| 125207201 | 12520720 | 15 | Prophylaxis of nausea and vomiting |
| 125207201 | 12520720 | 16 | Prophylaxis |
| 125207201 | 12520720 | 17 | Acquired immunodeficiency syndrome |
| 125207201 | 12520720 | 18 | Acquired immunodeficiency syndrome |
| 125207201 | 12520720 | 19 | Pain |
| 125207201 | 12520720 | 20 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125207201 | 12520720 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125207201 | 12520720 | Somnolence |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125207201 | 12520720 | 1 | 20160222 | 0 | ||
| 125207201 | 12520720 | 2 | 20160222 | 0 | ||
| 125207201 | 12520720 | 3 | 20160314 | 0 | ||
| 125207201 | 12520720 | 4 | 20160404 | 0 | ||
| 125207201 | 12520720 | 5 | 20160425 | 0 | ||
| 125207201 | 12520720 | 6 | 20160517 | 0 | ||
| 125207201 | 12520720 | 7 | 20160606 | 0 | ||
| 125207201 | 12520720 | 8 | 20160222 | 0 | ||
| 125207201 | 12520720 | 9 | 20160314 | 0 | ||
| 125207201 | 12520720 | 10 | 20160404 | 0 | ||
| 125207201 | 12520720 | 11 | 20160425 | 0 | ||
| 125207201 | 12520720 | 12 | 20160517 | 0 | ||
| 125207201 | 12520720 | 13 | 20160606 | 0 | ||
| 125207201 | 12520720 | 14 | 20160222 | 0 | ||
| 125207201 | 12520720 | 15 | 20160222 | 0 | ||
| 125207201 | 12520720 | 17 | 20160225 | 0 | ||
| 125207201 | 12520720 | 19 | 201601 | 0 | ||
| 125207201 | 12520720 | 20 | 20160225 | 0 |